France· FR:68082491
URAPIDIL STRAGEN LP 30 mg, gélule à libération prolongée
A urapidil product containing urapidil, registered in France by STRAGEN-FRANCE, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Urapidil is registered in 10 of 19 countries.
Countries holding a registration under ATC C02CA06 (urapidil), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 6 of them publish a price we can compare per daily dose
Urapidil · ATC C02CA06
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Franceprice
- Germany
- Japan
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- URAPIDIL
- Manufacturer
- STRAGEN-FRANCE
- Country
- France (FR)
- ATC code
- C02CA06
- ATC class
- Urapidil
- Defined daily dose
- 0.12 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009300828671 flacon(s) polypropylène de 30 gélule(s)EUR 3.15
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Urapidil in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEBRANTIL RETARDCHEPLAPHARM Arzneimittel GmbH, Greifswald
- GermanyEbrantilCheplapharm Arzneimittel Gmbh
- PolandEbrantil 25CHEPLAPHARM Arzneimittel GmbH
- NetherlandsUrapidil ERC 50 mg oplossing voor injectie/infusieEuro Registratie Collectief B.V.
- SpainELGADIL 5 mg/ml SOLUCION INYECTABLE Y PARA PERFUSIONCheplapharm Arzneimittel Gmbh
- SwitzerlandEbrantil 50 mg, InjektionslösungCheplapharm Schweiz GmbH
- BelgiumEbrantil IV 25 5 mg/mlTakeda Belgium
- United KingdomUrapidil 60mg capsulesImported (Switzerland)
Authorised across Europe · EMA
The same active substance is authorised in 17 EEA countries. Names it is sold under:
- Austria · Ebrantil, Galluper
- Belgium · Ebrantil I.V. 50
- Czechia · Ebrantil, Ebrantil Retard
- Germany · Ebrantil, Emersil I.V.
- Estonia · Urapidil Kalceks
- Spain · Urapidil Accord, Urapidil Kalceks
- Croatia · Ebrantil, Urapidil Kalceks
- Hungary · Ebrantil, Urapidil Kalceks
- Italy · Ebrantil, Urapidil Kalceks
- Luxembourg · Ebrantil I.V.
- Latvia · Urapidil Kalceks
- Netherlands · Urapidil Kalceks
- Poland · Ebrantil, Tachyben
- Portugal · Urapidil Kalceks, Urapidilo
- Romania · Tachyben, Urapidil Kalceks
- Slovenia · Ebrantil, Urapidil Kalceks
- Slovakia · Desurol, Ebrantil
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e5407693-d36a-46bf-90d9-044302dcf54b GET /v1/drugs/e5407693-d36a-46bf-90d9-044302dcf54b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68082491",
"date_amm": "2017-01-30",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "URAPIDIL",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule à libération prolongée",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about urapidil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.